Scientific Presentations
ForeseeHome
ARVO 2010 Annual Meeting
| April 2010
Stability in Statistical Distribution of Test Scores Obtained by Intermediate AMD Patients Monitored With a Home Device Perimeter
M. Goldstein; A. Loewenstein; Y. Lang; H. Katz; J. R. Ferencz; D. B. Roth; H. F. Fine; J. M. Weston; N. Mehta; R. JohnstonIn patients with intermediate AMD frequently monitored with the ForeseeHome for several months, statistical distribution of test scores is stable over time.
FDA Intended Use
ForeseeHome has not been approved by FDA for use other than described in the following Indication for Use: The ForeseeHome is intended for use in the detection and characterization of central and paracentral metamorphopsia (visual distortion) in patients with age-related macular degeneration as an aid in monitoring progression of disease factors causing metamorphopsia including, but not limited to choroidal neovascularization (CNV). It is intended to be used at home for patients with stable fixation.
Media enquiries? Reach out to our Media Contact
